Company Overview of Edison Pharmaceuticals, Inc.
Edison Pharmaceuticals, Inc. develops medicines for the treatment of inherited mitochondrial diseases. It offers EPI-743 and EPI-A0001 orally absorbed small molecules. Edison Pharmaceuticals, Inc. has a strategic alliance with Dainippon Sumitomo Pharma Co., Ltd. The company was founded in 2005 and is based in Mountain View, California with additional offices in the Netherlands. Edison Pharmaceuticals, Inc. operates as a subsidiary of Galileo Pharmaceuticals, Inc.
350 North Bernardo Avenue
Mountain View, CA 94043
Founded in 2005
Key Executives for Edison Pharmaceuticals, Inc.
Chairman and Chief Executive Officer
Corporate Counsel and Secretary
Vice President of Intellectual Property
Vice President of Research & Development
Compensation as of Fiscal Year 2015.
Edison Pharmaceuticals, Inc. Key Developments
Edison Pharmaceuticals, Inc. Presents at BioNetwork Partnering Summit, Oct-26-2015 10:00 AM
Oct 23 15
Edison Pharmaceuticals, Inc. Presents at BioNetwork Partnering Summit, Oct-26-2015 10:00 AM. Venue: The Ritz-Carlton, Laguna Niguel, California, United States. Speakers: Guy Miller, Chairman and Chief Executive Officer.
Edison Pharmaceuticals, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 02:00 PM
Jan 6 15
Edison Pharmaceuticals, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 02:00 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Guy Miller, Chairman and Chief Executive Officer.
Edison Pharmaceuticals, Inc. Announces Phase 2 Positive Clinical Results for EPI-743 in Rett Syndrome
Sep 3 14
Edison Pharmaceuticals, Inc. announced results of a recently completed phase 2 placebo-controlled trial in pediatric patients. Rett syndrome patients treated with EPI-743 demonstrated a statistically significant increase in head circumference. Decreased brain growth and head circumference are hallmarks of the disease. Rett syndrome is a genetic neurodevelopmental disorder predominately affecting girls, and is usually diagnosed by 24 months of age. It is characterized by a constellation of neurological, behavioral, functional, and structural features. These include delayed development, characteristic hand wringing, seizures, impaired respiratory function, slowing of brain growth, and resultant diminished head size, as well as other neurological disorders. The double-blind, placebo-controlled clinical trial was conducted at the General University Hospital (Azienda Ospedaliera Universitaria Senese) of Siena. A total of 24 subjects, 2.5 to 8 years of age, were enrolled in the six-month trial. While the study did not meet the primary endpoint of improving the subjective Rett syndrome disease severity score, subjects treated with EPI-743 demonstrated an objective improvement in head growth. Specifically, head growth in the treatment group was 0.75 cm from baseline, compared to 0.29 cm in the placebo group (p=0.05). In a subgroup analysis of the children with the large head growth, improvements in oxygenation, hand function, and disease-relevant biomarkers were also recorded. These data will be submitted for publication in the near future.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|